MYC and CD4+/CD56+ hematodermic neoplasm: Since 2018, MYC rearrangements (8q24) have been largely described in approximately 30% of BPDCN [29,37,38,39], with a more frequent immunoblastoid morphology and sometimes a CD56-negative phenotype [37,40].